These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22049203)

  • 1. Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
    Nagy AJ; Gandhi S; Bhola R; Goadsby PJ
    Neurology; 2011 Nov; 77(20):1827-32. PubMed ID: 22049203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing and administration of ergotamine tartrate and dihydroergotamine.
    Mathew NT
    Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Transformed migraine--chronic daily headache].
    Bøe MG; Monstad P
    Tidsskr Nor Laegeforen; 1999 Nov; 119(29):4311-3. PubMed ID: 10667127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine.
    Charles JA; von Dohln P
    Headache; 2010 May; 50(5):852-60. PubMed ID: 20132337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
    Silberstein SD; Young WB; Hopkins MM; Gebeline-Myers C; Bradley KC
    Headache; 2007 Jun; 47(6):878-85. PubMed ID: 17578539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
    Pradalier A; Guérard des Lauriers A; Scheck F; Peraudeau P; Lacoste JP; Cajfinger F
    Pathol Biol (Paris); 1995 Nov; 43(9):806-13. PubMed ID: 8746103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient continuous intravenous dihydroergotamine for refractory headache.
    Charles JA
    Headache; 2005 Apr; 45(4):394-5. PubMed ID: 15836585
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
    Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
    Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aprepitant for the management of nausea with inpatient IV dihydroergotamine.
    Chou DE; Tso AR; Goadsby PJ
    Neurology; 2016 Oct; 87(15):1613-1616. PubMed ID: 27629088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and Cost of Inpatient Hospitalization for Intravenous Dihydroergotamine Treatment of Refractory Pediatric Headache.
    Nelson GR; Bale JF; Kerr LM
    Pediatr Neurol; 2017 Jan; 66():76-81. PubMed ID: 27847180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Theroux LM; Cappa R; Mendoza A; Mallawaarachchi I; Samanta D; Goodkin HP
    Headache; 2020 Sep; 60(8):1653-1663. PubMed ID: 32853454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
    Stillman MJ; Zajac D; Rybicki LA
    Headache; 2004 Jan; 44(1):65-9. PubMed ID: 14979885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
    Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
    Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.
    Edwards KR; Norton J; Behnke M
    Headache; 2001; 41(10):976-80. PubMed ID: 11903525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive dihydroergotamine nasal spray for treatment of refractory headaches: an open-label pilot study.
    Weintraub J
    Curr Med Res Opin; 2006 Oct; 22(10):2031-6. PubMed ID: 17022862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
    Swidan SZ; Lake AE; Saper JR
    Curr Pain Headache Rep; 2005 Feb; 9(1):65-70. PubMed ID: 15625028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
    Headache; 1995 Apr; 35(4):177-84. PubMed ID: 7775172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroergotamine: role in the treatment of migraine.
    Schürks M
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1141-8. PubMed ID: 19624283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M; Gelfand AA; Riggins NY; Shiboski S; Schankin C; Goadsby PJ
    Neurology; 2016 Mar; 86(9):856-9. PubMed ID: 26843569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.